Rinnerva

A biotech venture developing a disruptive treatment for ALS.

Biotechnology
Active
Ganei Tiqwa, Israel Founded 2023
Website ↗
Last updated 2026-08-21
Total raised
—
Stage
—
Founded
2023
Headcount
—
HQ
Ganei Tiqwa, Israel
Sector
Biotechnology

About

Rinnerva is a biotechnological startup developing a groundbreaking new treatment for amyotrophic lateral sclerosis (ALS). Their solution, developed following years of studying the basic mechanisms of the disease, targets hallmark pathology by dissolving TDP-43 aggregates with their lead compound 'G3-P1', delivers the treatment to the peripheral nervous system, and focuses on early intervention to halt deterioration and restore lost function.

Q&A

What is Rinnerva's primary focus?
Rinnerva is a biotechnology startup developing a disruptive treatment for Amyotrophic Lateral Sclerosis (ALS).
Where is Rinnerva headquartered?
Rinnerva is headquartered in Ganei Tiqwa, Israel.
What is the core technology behind Rinnerva's ALS treatment?
Rinnerva's core technology involves their lead compound 'G3-P1', a peptide therapeutic designed to dissolve TDP-43 aggregates, which are a hallmark pathology of ALS.
Who are some key executives at Rinnerva?
Dr. Amir Dori M.D., Ph.D. serves as CMO, and Prof. Jeffery L. Twiss M.D., Ph.D. is the President and Chairman of the board.
What is the target market for Rinnerva's treatment?
Rinnerva's target market is the treatment of Amyotrophic Lateral Sclerosis (ALS).

Team · 2

Dr. Amir Dori M.D., Ph.D.
CMO, Head of the Neuromuscular clinic at Sheba Tel HaShomer medical center, Israel
Prof. Jeffery L. Twiss M.D., Ph.D.
President and Chairman of the board, Head of the neural repair and nerve regeneration research group, center for Childhood Neurotherapeutics, University

Sectors & technology

Primary sector
Biotechnology
Technologies
Target customers
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)